{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:22Z","timestamp":1792785862339,"version":"4.5.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["#22\/262"],"award-info":[{"award-number":["#22\/262"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Research Council of New Zealand Emerging Researcher Award 2024","award":["24\/659\/A"],"award-info":[{"award-number":["24\/659\/A"]}],"id":[{"id":"https:\/\/ror.org\/00zbf3d93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"New Zealand Society of Gastroenterology Janssen Research Fellowship 2023"},{"name":"Healthcare Otago Trust 22HCO-2"},{"name":"University of Otago Dean\u2019s Bequest Fund","id":[{"id":"https:\/\/ror.org\/01jmxt844","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK056008"],"award-info":[{"award-number":["DK056008"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Otago M\u0101ori Summer Studentship Scholarship and a University of Otago M\u0101ori Masters Scholarship","id":[{"id":"https:\/\/ror.org\/01jmxt844","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Type I interferons (IFN-Is) are central regulators of intestinal epithelial homeostasis, yet their role in driving epithelial dysfunction and therapeutic non-response in Crohn\u2019s disease (CD) remains poorly defined. Here, we investigated epithelial tumor necrosis factor (TNF)\u2013IFN-I crosstalk as a previously unrecognized contributor to anti-TNF non-response in CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed human intestinal biopsies, single-cell RNA sequencing data from CD donors, and used murine TNFR1-deficient and patient-derived organoids exposed to inflammatory cytokines and clinically relevant treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Colonic epithelia from anti-TNF non-responders (NR-CD) showed enrichment of IFN-I genes associated with epithelial stress, impaired regeneration, and inflammatory cytokine production. Using patient-derived and murine TNFR1-deficient organoids, we demonstrated that TNF signaling sustains epithelial IFN-I responses linked to immune regulation and antiviral pathways, establishing a mechanistic connection between chronic TNF signaling and epithelial barrier failure. Low-dose butyrate (0.1\u2009mM) suppressed cytokine-induced IFN-I genes and enhanced epithelial turnover in non-IBD and responder CD (R-CD) organoids but did not rescue the apoptosis and defective repair characteristic of NR-CD organoids. Notably, anti-IFN-I antibody treatment selectively attenuated IFN-I signaling and restored epithelial integrity in NR-CD organoids, identifying epithelial IFN-I blockade as a novel therapeutic rescue strategy for anti-TNF refractory disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TNF\u2013IFN-I crosstalk drives epithelial dysfunction in CD. Elevated epithelial IFN-I genes distinguish anti-TNF non-responders and underlie differential therapeutic responses. Together, this work supports integration of epithelial IFN-I gene expression and patient-derived ex vivo functional testing into treatment decisions for CD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag140","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:29:55Z","timestamp":1788521395000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeting epithelial IFN-I signaling restores barrier integrity in anti-TNF refractory Crohn\u2019s disease"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8424-8355","authenticated-orcid":false,"given":"Safina","family":"Gadeock","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Division of Health Sciences, University of Otago , Dunedin, Otago,","place":["New Zealand"]},{"name":"Division of Pediatric Gastroenterology and Nutrition, The Saban Research Institute, Children\u2019s Hospital Los Angeles , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikayla","family":"King","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Division of Health Sciences, University of Otago , Dunedin, Otago,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Brent","family":"Polk","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology and Nutrition, The Saban Research Institute, Children\u2019s Hospital Los Angeles , Los Angeles, CA,","place":["United States"]},{"name":"Department of Pediatrics, School of Medicine, University of California San Diego , La Jolla, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Highton","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Division of Health Sciences, University of Otago , Dunedin, Otago,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Division of Health Sciences, University of Otago , Dunedin, Otago,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Health Sciences, University of Otago , Dunedin, Otago,","place":["New Zealand"]},{"name":"Department of Medicine, Gastroenterology, Health New Zealand , Dunedin, Otago,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3116-0747","authenticated-orcid":false,"given":"Michael","family":"Schultz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Health Sciences, University of Otago , Dunedin, Otago,","place":["New Zealand"]},{"name":"Department of Medicine, Gastroenterology, Health New Zealand , Dunedin, Otago,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn A","family":"Kemp","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Division of Health Sciences, University of Otago , Dunedin, Otago,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"2026091913471639900_jjag140-B1","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","article-title":"25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future","volume":"70","author":"Haens","year":"2021","journal-title":"Gut"},{"key":"2026091913471639900_jjag140-B2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijmm.2014.02.009","article-title":"Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish irritable bowel syndrome and inflammatory bowel disease phenotypes","volume":"304","author":"Lopez-Siles","year":"2014","journal-title":"Int J Med Microbiol"},{"key":"2026091913471639900_jjag140-B3","doi-asserted-by":"crossref","first-page":"e00188","DOI":"10.1128\/msystems.00188-17","article-title":"Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction","volume":"3","author":"Zhou","year":"2018","journal-title":"mSystems"},{"key":"2026091913471639900_jjag140-B4","doi-asserted-by":"crossref","first-page":"127660","DOI":"10.1016\/j.micres.2024.127660","article-title":"Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review","volume":"282","author":"Wang","year":"2024","journal-title":"Microbiol Res"},{"key":"2026091913471639900_jjag140-B5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tim.2023.07.014","article-title":"Beyond butyrate: microbial fiber metabolism supporting colonic epithelial homeostasis","volume":"32","author":"Fagundes","year":"2024","journal-title":"Trends Microbiol"},{"key":"2026091913471639900_jjag140-B6","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3390\/cells10071775","article-title":"Butyrate and the intestinal epithelium: modulation of proliferation and inflammation in homeostasis and disease","volume":"10","author":"Salvi","year":"2021","journal-title":"Cells"},{"key":"2026091913471639900_jjag140-B7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/embor.2012.96","article-title":"Innate immune signalling at the intestinal epithelium in homeostasis and disease","volume":"13","author":"Pott","year":"2012","journal-title":"EMBO Rep"},{"key":"2026091913471639900_jjag140-B8","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.3390\/nu15102275","article-title":"Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: a literature review","volume":"15","author":"Recharla","year":"2023","journal-title":"Nutrients"},{"key":"2026091913471639900_jjag140-B9","first-page":"125","article-title":"Inflammatory bowel disease pathobiology: the role of the interferon signature","volume":"33","author":"Andreou","year":"2020","journal-title":"Ann Gastro\u00adenterol."},{"key":"2026091913471639900_jjag140-B10","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1093\/ibd\/izaf143","article-title":"Mucosal responses to type II interferon in IBD","volume":"31","author":"Cohen","year":"2025","journal-title":"Inflamm Bowel Dis."},{"key":"2026091913471639900_jjag140-B11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/ibd\/izaa216","article-title":"Type I and II interferon signatures can predict the response to anti-TNF agents in inflammatory bowel disease donors: involvement of the microbiota","volume":"26","author":"Gazouli","year":"2020","journal-title":"Inflamm. Bowel Dis"},{"key":"2026091913471639900_jjag140-B12","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar2912","article-title":"Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment","volume":"12","author":"van Baarsen","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2026091913471639900_jjag140-B13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.immuni.2019.03.017","article-title":"Cytokine networks in the pathophysiology of inflammatory bowel disease","volume":"50","author":"Friedrich","year":"2019","journal-title":"Immunity"},{"key":"2026091913471639900_jjag140-B14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","article-title":"Type I interferons in host defense","volume":"25","author":"Stetson","year":"2006","journal-title":"Immunity"},{"key":"2026091913471639900_jjag140-B15","doi-asserted-by":"crossref","first-page":"e00326-20","DOI":"10.1128\/JVI.00326-20","article-title":"Butyrate reprograms expression of specific interferon-stimulated genes","volume":"94","author":"Chemudupati","year":"2020","journal-title":"J Virol"},{"key":"2026091913471639900_jjag140-B16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fcell.2020.00363","article-title":"Characterization of human colon organoids from inflammatory bowel disease patients","volume":"8","author":"d\u2019Aldebert","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026091913471639900_jjag140-B17","doi-asserted-by":"crossref","first-page":"e1407","DOI":"10.1002\/cti2.1407","article-title":"An autologous colonic organoid-derived monolayer model to study immune-bacterial interactions in Crohn\u2019s disease donors","volume":"11","author":"Angus","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"2026091913471639900_jjag140-B18","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.08.674949","article-title":"Tumor necrosis factor signaling promotes differentiation of colonic deep crypt secretory cells","author":"Gadeock","year":"2025","journal-title":"bioRxiv"},{"key":"2026091913471639900_jjag140-B19","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in ulcerative colitis","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"key":"2026091913471639900_jjag140-B20","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and inter-cellular rewiring of the human colon during ulcerative colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"key":"2026091913471639900_jjag140-B21","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1073\/pnas.0913635107","article-title":"A method of mining developmentally regulated genes using Boolean implications","volume":"107","author":"Sahoo","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026091913471639900_jjag140-B22","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.gastro.2018.05.028","article-title":"Abnormal small intestinal epithelial microvilli in Crohn\u2019s disease","volume":"155","author":"VanDussen","year":"2018","journal-title":"Gastroenterology"},{"key":"2026091913471639900_jjag140-B23","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/ibd.21263","article-title":"Characterization of intestinal gene expression profiles in Crohn\u2019s disease by genome-wide microarray analysis","volume":"16","author":"Noble","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2026091913471639900_jjag140-B24","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cgh.2019.08.030","article-title":"Expression levels of 4 genes in colon tissue might be used to predict which donors will enter endoscopic remission after vedolizumab therapy for inflammatory bowel diseases","volume":"18","author":"Verstockt","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091913471639900_jjag140-B25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ibd.21108","article-title":"Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency","volume":"16","author":"Thibault","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2026091913471639900_jjag140-B26","doi-asserted-by":"crossref","first-page":"e87899","DOI":"10.1172\/jci.insight.87899","article-title":"Characterization of candidate genes in inflammatory bowel disease-associated risk loci","volume":"1","author":"Peloquin","year":"2016","journal-title":"JCI Insight"},{"key":"2026091913471639900_jjag140-B27","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026091913471639900_jjag140-B28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcmgh.2016.09.007","article-title":"Interferon-alpha promotes Th1 response and epithelial apoptosis via inflammasome activation in human intestinal mucosa","volume":"3","author":"Jarry","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026091913471639900_jjag140-B29","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1084\/jem.20090213","article-title":"Type I interferon drives TNF-induced lethal shock","volume":"206","author":"Huys","year":"2009","journal-title":"J Exp Med"},{"key":"2026091913471639900_jjag140-B30","doi-asserted-by":"crossref","first-page":"e31939","DOI":"10.1371\/journal.pone.0031939","article-title":"Interleukin-7 links T lymphocyte and intestinal epithelial cell homeostasis","volume":"7","author":"Shalapour","year":"2012","journal-title":"PLoS One"},{"key":"2026091913471639900_jjag140-B31","first-page":"3","article-title":"Role of interferon alpha-inducible protein 6 in modulating the proliferation, apoptosis and senescence of oesophageal squamous cell carcinoma cells","volume":"74","author":"Gao","year":"2023","journal-title":"J Physiol Pharmacol"},{"key":"2026091913471639900_jjag140-B32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12931-024-03046-z","article-title":"Intestinal IFN\u03b14 promotes diet-induced pulmonary hypertension","volume":"25","author":"Ruffenach","year":"2024","journal-title":"Respir Res"},{"key":"2026091913471639900_jjag140-B33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","article-title":"Mechanisms of inflammatory bowel diseases","volume":"94","author":"Ramos","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2026091913471639900_jjag140-B34","first-page":"03134","article-title":"GPCR screening reveals that the metabolite receptor HCAR3 regulates epithelial proliferation, migration, and cellular respiration","volume":"S0022-202X","author":"Pedro","year":"2023","journal-title":"J. Invest Dermatol"},{"key":"2026091913471639900_jjag140-B35","doi-asserted-by":"crossref","first-page":"S-1353","DOI":"10.1016\/S0016-5085(24)03558-3","article-title":"Type I interferon targets as predictors of clinical non-response to anti-TNFs in IBD patients and their regulation of epithelial repair responses","volume":"166","author":"Gadeock","year":"2024","journal-title":"Gastroenterology"},{"key":"2026091913471639900_jjag140-B36","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-alpha\/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026091913471639900_jjag140-B37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"2026091913471639900_jjag140-B38","doi-asserted-by":"crossref","first-page":"1713424","DOI":"10.3389\/fmed.2025.1713424","article-title":"Type I interferons in inflammatory bowel diseases: balancing barrier integrity, repair and inflammation in the intestinal epithelium","volume":"12","author":"King","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026091913471639900_jjag140-B39","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1126\/science.abc2061","article-title":"Type I and III interferons disrupt epithelial repair during recovery from viral infection","volume":"369","author":"Major","year":"2020","journal-title":"Science"},{"key":"2026091913471639900_jjag140-B40","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/eji.201344401","article-title":"Type I interferons have opposing effects during the emergence and recovery phases of colitis","volume":"44","author":"Rauch","year":"2014","journal-title":"Eur J Immunol"},{"key":"2026091913471639900_jjag140-B41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.31138\/mjr.270324.tis","article-title":"Type I interferons in systemic autoimmune rheumatic diseases: pathogenesis, clinical features and treatment options","volume":"35","author":"Drougkas","year":"2024","journal-title":"Mediterr. J Rheumatol"},{"key":"2026091913471639900_jjag140-B42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.ircmb.2019.10.004","article-title":"Type I interferons and endoplasmic reticulum stress in health and disease","volume":"350","author":"Sprooten","year":"2020","journal-title":"Int Rev Cell Mol Biol"},{"key":"2026091913471639900_jjag140-B43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/imr.13318","article-title":"Metabolic regulation of type I interferon production","volume":"323","author":"O\u2019Carroll","year":"2024","journal-title":"Immunol Rev"},{"key":"2026091913471639900_jjag140-B44","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2353\/ajpath.2010.100168","article-title":"Cytoskeletal regulation of epithelial barrier function during inflammation","volume":"177","author":"Ivanov","year":"2010","journal-title":"Am J Pathol"},{"key":"2026091913471639900_jjag140-B45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/ibd\/izae232","article-title":"Intestinal epithelial tight junction barrier regulation by novel pathways","volume":"31","author":"Arumugam","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026091913471639900_jjag140-B46","doi-asserted-by":"crossref","first-page":"101372","DOI":"10.1016\/j.isci.2020.101372","article-title":"Spatiotemporal gradient and instability of Wnt induce heterogeneous growth and differentiation of human intestinal organoids","volume":"23","author":"Shin","year":"2020","journal-title":"iScience"},{"key":"2026091913471639900_jjag140-B47","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.cell.2006.01.041","article-title":"The response of human epithelial cells to TNF involves an inducible autocrine cascade","volume":"124","author":"Janes","year":"2006","journal-title":"Cell"},{"key":"2026091913471639900_jjag140-B48","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026091913471639900_jjag140-B49","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3390\/ph14090840","article-title":"JAK-STAT pathway regulation of intestinal permeability: pathogenic roles and therapeutic opportunities in inflammatory bowel disease","volume":"14","author":"Lei","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026091913471639900_jjag140-B50","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2026091913471639900_jjag140-B51","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4049\/jimmunol.150.3.707","article-title":"A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor","volume":"150","author":"Benoit","year":"1993","journal-title":"J Immunol"},{"key":"2026091913471639900_jjag140-B52","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2147\/DDDT.S170969","article-title":"Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date","volume":"13","author":"Felten","year":"2019","journal-title":"Drug Des Devel Ther"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/9\/jjag140\/71236208\/jjag140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/9\/jjag140\/71236208\/jjag140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:48:57Z","timestamp":1789840137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag140\/8818166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag140","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9]]},"article-number":"jjag140"}}